Edition:
United Kingdom

Supernus Pharmaceuticals Inc (SUPN.OQ)

SUPN.OQ on NASDAQ Stock Exchange Global Market

39.40USD
23 Feb 2018
Change (% chg)

$0.95 (+2.47%)
Prev Close
$38.45
Open
$38.55
Day's High
$39.70
Day's Low
$38.15
Volume
91,819
Avg. Vol
177,038
52-wk High
$50.03
52-wk Low
$24.65

Chart for

About

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In... (more)

Overall

Beta: 1.30
Market Cap(Mil.): $2,149.64
Shares Outstanding(Mil.): 50.70
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.91 10.66
ROE: -- 16.41 14.30

BRIEF-Supernus announces third quarter 2017 financial results

* Q3 earnings per share view $0.27 -- Thomson Reuters I/B/E/S

06 Nov 2017

Competitors

  Price Chg
Abbott Laboratories (ABT.N) $59.71 +0.72
AstraZeneca plc (AZN.L) 4,752.00 -20.00
Eli Lilly and Co (LLY.N) $78.75 +1.56
Shire PLC (SHP.L) 3,024.00 -13.00
Shire PLC (3159084.L) -- --
Smiths Group plc (SMIN.L) 1,588.00 -1.50

Earnings vs. Estimates